Lv51
830 积分 2022-10-28 加入
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology
1小时前
已完结
Treatment De-escalation in AQP4-Ab Neuromyelitis Optica Spectrum Disorder
3个月前
已完结
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch
4个月前
已完结
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study
5个月前
已关闭
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study
5个月前
已完结
Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults
5个月前
已完结
Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation
6个月前
已完结
Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study
6个月前
已完结
Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: A modeling analysis of literature aggregate data
7个月前
已完结
Association of B cell Subsets and Aquaporin-4 antibody titers with Disease Activity in Participants in the N-MOmentum trial Receiving Inebilizumab Treatment (S5.005)
9个月前
已关闭
皖公网安备34019202002308
